🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧭 Heading to #ASCO25? Tips to make the most of the meeting: ✅ Plan your agenda early 🤝 Prioritize networking 📱 Use the app & follow #ASCO25 🧠 Preview the Ed Book 👟 Pack comfy shoes! ASCO

The first letter of the genetic code was cracked #OTD in 1961 at 3am by Marshall Nirenberg (right) and Heinrich Matthaei (left) at the NIH. Nirenberg shared the 1968 medicine prize with Har Gobind Khorana and Robert Holley for their work on the genetic code. #NobelPrize

Every year, Conquer Cancer, the ASCO Foundation funds the work of hundreds of researchers across the oncology community so we can continue making advances in the field... Driving Knowledge to Action and Building a Better Future! Consider supporting Conquer Cancer during #ASCO25 via the link below.

Time to treatment initiation for patients with cancer. From 2004-2015, treatment time⬆️7 days, from 21 to 28. Cancer stage (especially I) was biggest predictor for increase. pubmed.ncbi.nlm.nih.gov/40393016/ Gianna D'Afflisio Ming Wang_CWRU Daniel E Spratt Raed Zuhour Alok Khorana, MD Karl Bilimoria

🚨 New data from the BRAFTOVI BREAKWATER trial at ASCO 2025! 📊 📈51% reduced death risk for BRAF V600E colorectal cancer patients. 💊 🌟Survival: 30.3 months vs. 15.1 months. 📅 ARTICLE: oncologytube.com/braftovi-break… YouTube: youtu.be/N-FeOHE4YPY #ASC025 #ColorectalCancer

DYNAMIC-III study shows no benefit of giving more chemo for ctDNA+ stage 3 colon cancer. I always say, ctDNA is amazing and cool, but it doesn't make FOLFOX (or irinotecan) more effective. #ASCO25 #CancerCare

New research from NBCA’s Alok Khorana, MD & Dana Angelini shows DOACs may lower the risk of bleeding, ICU stays & death vs. LMWH in cancer patients with brain metastases. 📍Poster #80 | #ASCO25 | 9 a.m. –12 p.m. 🔗 asco.org/abstracts-pres… 📍Visit NBCA at booth 13000! #StopTheClot

Full BREAKWATER paper here #ASCO25

Perioperative radiochemotherapy vs Gem/Cis in locally advanced gallbladder cancers #ASCO25 🔎POLCAGB phs-III 👉ORR 74% vs 35% 👉mEFS 10 vs 4.8 mo 👉mOS 21.8 vs 10 mo 🧐 small trial, but very interesting efficacy data in cT3/4 cN+ ESMO - Eur. Oncology @easledu ILCA Cholangiocarcinoma Foundation

Not all cancers are funded equally - in fact, the most lethal cancers get the LEAST funding. As federal money becomes more scarce, ensuring equitable funding across cancers is that much more important. #ASCO25 #CleClinicCancer

Benefit of "structured exercise" program for adjuvant colon cancer is honestly quite amazing but how do we operationalize in clinic? #ASCO25 nejm.org/doi/full/10.10…

LITESPARK-004 (5-yr f/u): Belzutifan in VHL disease–associated tumors (n=61) 🎯 ORR: • RCC: 70% • CNS HB: 50% • pNETs: 90% • Retinal HB: 100% improvement (18 eyes) ➡️57% still on tx at 5 yrs 🛡️ Grade 3 TRAEs: 18% (anemia most common) 🚫 No grade 4/5 TRAEs ✅Durable

Congratulations to 🇨🇦CCTG for this brilliant study- the most impactful at #ASCO2025 for my patients! 👉🏽Interesting to see exercise ⬇️ the risk of recurrence to liver, but lung and peritoneal mets did not appear to be impacted. 👉🏽Exercise reduced risk of new primary

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

The pharma miracle machine is almost entirely powered by the US. Instead of appreciating it, left and right are attacking on all fronts--price controls on the market side, cuts to the research funding side. Because no one can see past their immediate political priorities.

Great point and great The New York Times interactive article in which you can look up institutions and canceled grants. ➡️1,380 grants have been terminated this year compared to the usual of 20 per year. ➡️Call your Senators to ask them to vote against the proposed 40% cut to NIH budget

🔬 Colorectal Cancer (CRC) Screening: Evolving Landscape 🧻🩸🧪 📊 CRC = 2nd leading cause of cancer death, 3rd most common globally 👁️‍🗨️ Begins as adenomatous/serrated polyps → Advanced precursor lesions (APLs) → invasive cancer 🎯 Goal of screening: Detect early-stage CRC &

Seven years ago, what seemed like a normal day for Leslie L. Lake turned into a fight for her life. Today marks her 7th clotiversary. Now President of NBCA, Leslie is using her experience to raise awareness and save lives. 🔗Watch her story via AARP: aarp.org/videos/health/…

Announcing the first EVER Journal of Clinical Oncology Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…

🧬 Early ctDNA Dynamics Predict ICI Outcomes in MSI-H mCRC! 📌 In the SAMCO-PRODIGE 54 RCT (n=99), change in ctDNA at 1 month—not baseline levels—strongly predicted: ✅ Progression-free survival (HR 2.98) ✅ Overall survival (HR 3.61) 💥 In avelumab-treated pts: 📉 Poor ctDNA